XCures Raises $46M Series B to Transform Medical Records With AI

XCures Raises $46M Series B to Transform Medical Records With AI

XCures, a health AI startup turning messy patient data into clinical intelligence, has closed a $46 million Series B funding round, the company exclusively told Crunchbase News.

Innovius Capital led the round, with participation from iGrow, Spring Mountain Capital, and existing investors. The raise brings XCures’ total funding to over $76 million since its 2018 founding and values the company at $127 million post-money more than double the valuation from its $25 million Series A closed in December 2023.

Turning Dirty Data Into Clinical Clarity

Founded as a spinout from Cancer Commons by Marty Tenenbaum, xCures initially built decision-support tools for advanced cancer patients. But the company quickly discovered that the biggest obstacle wasn’t decision-making it was the data itself. Patient records were arriving in FedEx boxes and over fax machines, riddled with duplicates, scanned images, and human entry errors.

That discovery prompted a strategic pivot. XCures built what it calls a Clinical Clarity Engine an AI medical records platform that plugs into national healthcare interoperability networks, ingesting unstructured patient data and converting it into decision-ready clinical intelligence. To date, the system has processed over 300 million medical records from more than 550,000 healthcare locations across the U.S.

“The data in those medical records is incredibly dirty,” said CEO Mika Newton. “We turn it all into something that is clinical intelligence an organization needs to make its next decisions.”

The AI medical records engine operates on a usage-based SaaS model. XCures grew from $3 million to $10 million in annualized recurring revenue in 2025, and is on track to surpass $20 million in 2026. Its 25 enterprise clients include Exact Sciences, Caris Life Sciences, and Novocure, alongside large hospital networks, telehealth providers, and Medicare Advantage plans.

The new capital will fund team expansion in preparation for its 2027 business pipeline.